SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Cancer Epidemiology and Prevention
This article is part of the Research TopicDNA Methylation Detection in Aging Populations: Implications for Early Diagnosis and Prognosis of Malignant TumorsView all articles
Utility and clinical effectiveness of liquid biopsy-based DNA methylation testing in early tumor screening and diagnosis, emphasizing older adult populations: A systematic review and meta-analysis
Provisionally accepted
- Nanjing University, Nanjing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The global aging population faces a disproportionate burden of lung cancer, creating an urgent need for minimally invasive screening methods. Liquid biopsy-based DNA methylation testing, particularly targeting the cysteine dioxygenase type 1 (CDO1) gene promoter, has emerged as a promising approach for early cancer detection. This study aims to systematically evaluate the diagnostic value 要点, 字体: (默认)Times New Roman, (中文)Segoe UI, 小四, 非加粗, 图案: 清除(白色), 字体 颜色: 自定义颜色(RGB(15,17,21)) 设置格式[AE]: of CDO1 promoter methylation in lung cancer using liquid biopsies. Methods: A comprehensive literature search was conducted across PubMed/MEDLINE, Embase, Web of Science, and Cochrane Library from inception to 28Th September, 2025. Studies reporting CDO1 promoter methylation in liquid biopsies (blood, urine, or sputum) for lung cancer detection with histological confirmation were included. Methodological quality was assessed using QUADAS-2. Bivariate random-effects models were used to calculate pooled sensitivity, specificity, diagnostic odds ratio (DOR), positive/negative likelihood ratios (PLR/NLR), and 95% confidence intervals. Results: Seven studies involving 655 lung cancer cases and 402 controls were included. CDO1 methylation demonstrated pooled sensitivity of 0.72 and specificity of 0.89 for blood-based liquid biopsies, and 0.66 and 0.87 for non-blood specimens, respectively. The overall diagnostic odds ratio was 19.13 (95% CI: 13.53-26.84), with positive and negative likelihood ratios of 7.73 (95% CI: 5.77-10.35) and 0.32 (95% CI: 0.26-0.39). No significant heterogeneity was observed across studies (I² = 0% for all parameters). Subgroup analyses revealed consistent performance across different specimen types and geographic regions. Conclusion: CDO1 promoter methylation detection in liquid biopsies shows robust diagnostic accuracy for lung cancer, with performance characteristics supporting its potential clinical utility, particularly for older populations who face barriers to conventional screening. The consistency across diverse specimen types and populations underscores its promise as a minimally invasive screening tool.
Keywords: Aging Population, Cdo1, DNA Methylation, early diagnosis, liquid biopsy, lung cancer
Received: 05 Nov 2025; Accepted: 19 Dec 2025.
Copyright: © 2025 Gao, Xu, Li, Li and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Desheng Zhu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.